Literature DB >> 12549803

Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.

Sarayut Supapannachart1, Anchalee Limrungsikul, Pongsak Khowsathit.   

Abstract

BACKGROUND: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA). The efficacy of ibuprofen is comparable to indomethacin in many clinical trials with fewer renal side effects. However, the intravenous form of ibuprofen is not available in Thailand, whereas, the oral suspension form is widely used for antipyretic treatment in children. Therefore, the authors investigated the possibilities of using oral ibuprofen for the treatment of PDA in premature newborn infants.
OBJECTIVE: To assess whether oral ibuprofen at 10 mg/kg/dose daily for 3 days was as effective as indomethacin to treat symptomatic PDA in premature infants and to compare the side effects of oral ibuprofen to indomethacin. SUBJECTS AND
METHOD: Eighteen premature infants with gestational ages less than 34 weeks born at Ramathibodi Hospital who developed symptomatic PDA were randomly assigned to receive three doses of either indomethacin (oral or intravenous administration 0.2 mg/kg/dose for three doses given at 12 hourly intervals or oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals). The rates of ductal closure, infants' clinical courses, side effects and complications were recorded.
RESULTS: Birth weight, gestational age, gender, age onset and number of infants who had respiratory distress syndrome were similar in both groups, PDA was closed in 7 of 9 infants given ibuprofen (78%) and in 8 of 9 infants given indomethacin (89%) (p > 0.05). The mean plasma concentration of ibuprofen was 28.05 microg/ml at 1 hour after the third dose. Neonates in the ibuprofen group had more urine output. However, the increment of serum BUN and creatinine were not significantly different in both groups. There were no significant differences in duration of ventilator support as well as number of patients with bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis and death in both groups.
CONCLUSION: Oral ibuprofen therapy is as effective as indomethacin for the treatment of PDA in premature infants and seems to have fewer renal side effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12549803

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  11 in total

1.  Pharmacoeconomics of Surgical Interventions vs. Cyclooxygenase Inhibitors for the Treatment of Patent Ductus Arteriosus.

Authors:  Charles J Turck; Wallace Marsh; James G Stevenson; John M York; Henry Miller; Snehal Patel
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

2.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

3.  Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial.

Authors:  Sanju Yadav; Sheetal Agarwal; Arti Maria; Ajay Dudeja; N K Dubey; Puneet Anand; Dinesh Kumar Yadav
Journal:  Pediatr Cardiol       Date:  2014-01-17       Impact factor: 1.655

Review 4.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 5.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

7.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

8.  Factors affecting the effectiveness of oral ibuprofen in the treatment of patent ductus arteriosus in preterm infants.

Authors:  Chaohui Ye; Qin Lyu; Linyan Jiang; Li Yu; Yinquan Xu; Jie Zhang; Xiaodong Lu
Journal:  Int J Clin Pharm       Date:  2021-01-05

Review 9.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2018-09-28

10.  The Association between Patent Ductus Arteriosus and Perinatal Infection in A Group of Low Birth Weight Preterm Infants.

Authors:  Edmond Pistulli; Arjan Hamiti; Sokol Buba; Alketa Hoxha; Nita Kelmendi; Gentian Vyshka
Journal:  Iran J Pediatr       Date:  2013-11-22       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.